Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT04842604
Registration number
NCT04842604
Ethics application status
Date submitted
8/04/2021
Date registered
13/04/2021
Date last updated
16/12/2022
Titles & IDs
Public title
Continuation Study of B1371019(NCT03416179) and B1371012(NCT02367456) Evaluating Azacitidine With Or Without Glasdegib In Patients With Previously Untreated AML, MDS or CMML
Query!
Scientific title
A MULTI-CENTER CONTINUATION STUDY EVALUATING AZACITIDINE WITH OR WITHOUT GLASDEGIB (PF-04449913) IN PATIENTS WITH PREVIOUSLY UNTREATED ACUTE MYELOID LEUKEMIA, MYELODYSPLASTIC SYNDROME OR CHRONIC MYELOMONOCYTIC LEUKEMIA
Query!
Secondary ID [1]
0
0
2017-002822-19
Query!
Secondary ID [2]
0
0
B1371019 Open Label Extension
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Acute Myeloid Leukemia
0
0
Query!
Myelodysplastic Syndrome
0
0
Query!
Chronic Myelomonocytic Leukemia
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Leukaemia - Acute leukaemia
Query!
Cancer
0
0
0
0
Query!
Leukaemia - Chronic leukaemia
Query!
Cancer
0
0
0
0
Query!
Children's - Leukaemia & Lymphoma
Query!
Blood
0
0
0
0
Query!
Haematological diseases
Query!
Blood
0
0
0
0
Query!
Other blood disorders
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Glasdegib
Treatment: Drugs - Azacitidine
Experimental: Participants from B1371019 and B1371012 - Azacitidine will be administered 75 mg/m2/day for 7 days every 28 days on Days 1-7 (±3 days) per local label or per the IP Manual (or SPC). Azacitidine may be administered by SC injection or IV infusion. Alternate dosing schedules to administer the 7 doses to accommodate participant and treatment center availability are allowed.
The starting dose regimen will be the same as the most recent regimen received on the B1371019 or B1371012 study.
Glasdegib 50, 75 or 100 mg will be orally administered daily and continuously. The starting dose regimen will be the same as the most recent regimen received on the B1371012 or B1371019 study.
Treatment: Drugs: Glasdegib
25 mg or 100 mg tablet
Treatment: Drugs: Azacitidine
100 mg/vial powder for 25 mg/mL suspension for injection
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Number of participants with treatment related adverse events (TEAE)
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
Baseline through 28 days after last dose (up to approximately 20 months)
Query!
Primary outcome [2]
0
0
Number of participants with serious adverse events (SAE)
Query!
Assessment method [2]
0
0
Query!
Timepoint [2]
0
0
Baseline through 28 days after last dose (up to approximately 20 months)
Query!
Eligibility
Key inclusion criteria
- Any participant who continues to demonstrate clinical benefit (as determined by the
Principal Investigator) from study treatment with azacitidine with or without
glasdegib in this Study or from Study B1371012.
- Capable of giving signed informed consent as described in Appendix 1, which includes
compliance with the requirements and restrictions listed in the ICD and in this
protocol.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Other medical or psychiatric condition including recent (within the past year) or
active suicidal ideation/behavior or laboratory abnormality that may increase the risk
of study participation or, in the investigator's judgment, make the participant
inappropriate for the study.
- Female participants who are pregnant or breastfeeding (if continuing to receive study
intervention);
- Participant has been withdrawn from Study B1371019 and Study B1371012 for any reason
(including INT cohort participants required to end study treatment)
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Non-randomised trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Single group
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
17/05/2021
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
2/12/2022
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
15
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment outside Australia
Country [1]
0
0
Austria
Query!
State/province [1]
0
0
Salzburg
Query!
Country [2]
0
0
Canada
Query!
State/province [2]
0
0
Manitoba
Query!
Country [3]
0
0
Czechia
Query!
State/province [3]
0
0
Ostrava - Poruba
Query!
Country [4]
0
0
Czechia
Query!
State/province [4]
0
0
Ostrava-Poruba
Query!
Country [5]
0
0
France
Query!
State/province [5]
0
0
Nantes cedex 1
Query!
Country [6]
0
0
France
Query!
State/province [6]
0
0
Nantes cedex
Query!
Country [7]
0
0
Hungary
Query!
State/province [7]
0
0
Debrecen
Query!
Country [8]
0
0
Italy
Query!
State/province [8]
0
0
Ancona
Query!
Country [9]
0
0
Italy
Query!
State/province [9]
0
0
AN
Query!
Country [10]
0
0
Japan
Query!
State/province [10]
0
0
Fukui
Query!
Country [11]
0
0
Japan
Query!
State/province [11]
0
0
Osaka
Query!
Country [12]
0
0
Mexico
Query!
State/province [12]
0
0
MÉX
Query!
Country [13]
0
0
Poland
Query!
State/province [13]
0
0
Lodz
Query!
Country [14]
0
0
Spain
Query!
State/province [14]
0
0
Valencia
Query!
Country [15]
0
0
United Kingdom
Query!
State/province [15]
0
0
Surry
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Pfizer
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
An open-label study available to all eligible participants from Study B1371019 and
participants originating from Study B1371012 continuing on study intervention with
azacitidine with or without glasdegib.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT04842604
Query!
Trial related presentations / publications
Query!
Public notes
This record is viewable in the ANZCTR as it had previously listed Australia and/or New Zealand as a recruitment site, however these sites have since been removed
Query!
Contacts
Principal investigator
Name
0
0
Pfizer CT.gov Call Center
Query!
Address
0
0
Pfizer
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT04842604
Download to PDF